Brand innovator versus multisource cefpodoxime in respiratory tract infections: A comparative study
Purpose: In everyday practice clinicians are overwhelmed by claims from the pharmaceutical industry and, due to marketing efforts, they often view generic multisource products with scepticism despite proof and registration by regulatory authorities of bioequivalence. The primary aim of this study wa...
Main Authors: | J. R. Snyman, C. E. Medlen |
---|---|
Format: | Article |
Language: | English |
Published: |
AOSIS
2019-04-01
|
Series: | South African Family Practice |
Subjects: | |
Online Access: | https://safpj.co.za/index.php/safpj/article/view/5000 |
Similar Items
-
Antibacterial treatment of patients with acute infection of the upper respiratory tract
by: V. M. Svistushkin, et al.
Published: (2018-04-01) -
Study of the relative bioavailability of a multisource formulation of sulfamethoxazole regarding the drug reference
by: Alvarado Yarasca, et al.
Published: (2016-03-01) -
Motives for Multisourcing in the IT Sector
by: Łoboda Barbara
Published: (2014-10-01) -
Prevalence and antimicrobial susceptibility patterns of bacteria in ICU patients with lower respiratory tract infection: A cross-sectional study
by: Birasen Behera, et al.
Published: (2020-01-01) -
The microbiome of the upper respiratory tract in health and disease
by: Christina Kumpitsch, et al.
Published: (2019-11-01)